Pfizer (NYSE:PFE) Trading 1.6% Higher – Time to Buy?

Pfizer Inc. (NYSE:PFE) shares rose 1.6% during trading on Wednesday . The stock traded as high as $25.71 and last traded at $25.5580. Approximately 53,627,121 shares were traded during trading, an increase of 17% from the average daily volume of 45,800,254 shares. The stock had previously closed at $25.15.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported completion of a key China Phase 3 trial for its migraine drug rimegepant, which de-risks global regulatory and commercial rollout in a large market and supports future revenue growth. Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant
• Positive Sentiment: Pfizer launched a new bioequivalence study for a CGRP migraine asset (early-stage formulation work), signaling continued investment in migraine portfolio expansion and potential lower-cost or differentiated formulations. Pfizer Advances CGRP Migraine Asset With New Bioequivalence Study
• Positive Sentiment: CEO Albert Bourla said Pfizer is pushing for an FDA priority review voucher and is positioning for a large consumer market for obesity drugs (compared to Viagra-era demand), underlining management’s focus on faster regulatory paths and new high-growth categories. These comments support upside expectations if obesity assets and regulatory wins materialize. Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher
• Positive Sentiment: Management’s obesity strategy (including the $10B Metsera buy) and public guidance about a large consumer opportunity lend optionality to Pfizer’s longer-term growth profile. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology and obesity pipeline upside and post-loss-of-exclusivity recovery potential—an analyst voice supporting shares. Pfizer: Underappreciated Growth Story Driven by Oncology, Obesity Pipeline, and Post-LOE Recovery Prospects
• Neutral Sentiment: Institutional owners hold ~66% of Pfizer stock, which can stabilize trading but also concentrate influence on strategy and liquidity. Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company
• Neutral Sentiment: Analysts and previews expect steady oncology performance (Seagen ADCs and key brands) that could be offset by pricing and competition—results due with Q4 releases may be a near-term volatility trigger. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
• Negative Sentiment: Investors remain concerned after recent weakness in the stock (market cap decline) tied to conservative 2026 guidance; commentators debate whether downside is a buying opportunity or a sign to stay cautious. Guidance-related uncertainty is pressuring the multiple. PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
• Negative Sentiment: Pfizer stopped a mid-stage lupus skin trial, trimming a potential autoimmune opportunity—a small but negative pipeline read that increases clinical risk mix. Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option
• Negative Sentiment: Critical commentary highlights patent cliff risk, rising debt and the challenge of sustaining buy ratings—items that keep valuation and credit metrics under investor scrutiny. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Analyst Ratings Changes

PFE has been the topic of several research reports. Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, Scotiabank started coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $27.88.

Pfizer Stock Up 1.6%

The business’s fifty day moving average price is $25.29 and its two-hundred day moving average price is $24.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $145.32 billion, a P/E ratio of 14.86 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. State Street Corp raised its holdings in shares of Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after buying an additional 1,820,634 shares during the period. Norges Bank purchased a new stake in shares of Pfizer during the second quarter valued at $2,270,157,000. Finally, Northern Trust Corp grew its holdings in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.